Related Experiment Video
Updated: Mar 20, 2026
09:29
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
19.1K
Recent Progress in Triple Negative Breast Cancer Research
Fatima Zahra Mouh1, Mohammed El Mzibri, Meriem Slaoui
1Equipe deRecherche ONCOGYMA, University of Mohamed V, Faculty of Medicine and Pharmacy of Rabat Morocco
Asian Pacific Journal of Cancer Prevention : APJCP
|May 26, 2016
Summary
Triple-negative breast cancer (TNBC) is aggressive and lacks targeted therapies. Research highlights genetic and epigenetic biomarkers for improved diagnosis, prognosis, and targeted treatment strategies for TNBC.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Triple-negative breast cancer (TNBC) lacks estrogen/progesterone receptors (ER, PR) and HER2 expression.
- TNBC is characterized by high aggressiveness, poor survival rates, and limited targeted therapeutic options.
- Recent advancements have identified key molecular characteristics and potential biomarkers for TNBC.
Purpose of the Study:
- To review recent progress in triple-negative breast cancer research.
- To focus on genetic and epigenetic alterations in TNBC.
- To explore the utility of identified biomarkers in targeted therapy and patient management.
Main Methods:
- Literature review of recent TNBC research.
- Analysis of genetic and epigenetic alterations.
- Evaluation of biomarker potential for diagnosis, prognosis, and therapy.
Main Results:
- Identification of significant genetic and epigenetic alterations in TNBC.
- Discovery of potential biomarkers for TNBC diagnosis and prognosis.
- Emerging strategies for targeted therapy based on molecular characteristics.
Conclusions:
- Genetic and epigenetic alterations are crucial in TNBC pathogenesis.
- Biomarkers hold promise for personalized medicine approaches in TNBC.
- Targeted therapies informed by molecular insights can improve TNBC management.
Related Concept Videos
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
02:07Tumor Progression
7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K